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Abstract
The majority of cases of frontotemporal lobar degeneration and amyotrophic lateral sclerosis are pathologically defined by
the cleavage, cytoplasmic redistribution and aggregation of TAR DNA binding protein of 43 kDa (TDP-43). To examine the
contribution of these potentially toxic mechanisms in vivo, we generated transgenic mice expressing human TDP-43
containing the familial amyotrophic lateral sclerosis-linked M337V mutation and identified two lines that developed
neurological phenotypes of differing severity and progression. The first developed a rapid cortical neurodegenerative
phenotype in the early postnatal period, characterized by fragmentation of TDP-43 and loss of endogenous murine Tdp-43,
but entirely lacking aggregates of ubiquitin or TDP-43. A second, low expressing line was aged to 25 months without a
severe neurodegenerative phenotype, despite a 30% loss of mouse Tdp-43 and accumulation of lower molecular weight
TDP-43 species. Furthermore, TDP-43 fragments generated during neurodegeneration were not C-terminal, but rather were
derived from a central portion of human TDP-43. Thus we find that aggregation is not required for cell loss, loss of murine
Tdp-43 is not necessarily sufficient in order to develop a severe neurodegenerative phenotype and lower molecular weight
TDP-43 positive species in mouse models should not be inherently assumed to be representative of human disease. Our
findings are significant for the interpretation of other transgenic studies of TDP-43 proteinopathy.
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Introduction
TAR DNA binding protein of 43 kilodaltons (TDP-43) is the
major pathological substrate in frontotemporal lobar degeneration
with TDP-43 pathology (FTLD-TDP) and most cases of amyo-
trophic lateral sclerosis (ALS) [1]. TDP-43 is a member of the
hnRNP family, containing two RNA Recognition Motifs (RRMs)
that bind RNA and a C-terminal, glycine rich domain that
mediates interactions with functional binding partners to coordi-
nate the metabolism of a wide range of RNA substrates [2,3]. In
disease, normal nuclear localization of TDP-43 is lost, and
ubiquitinated and hyperphosphorylated inclusions are deposited in
the form of neuronal intranuclear inclusions or in the cytoplasm as
juxtanuclear aggregates or dystrophic neurites [4]. TDP-43 also
undergoes processing to produce C-terminal fragments that range
in size from 15–35 kDa [1,5,6]. Evidence for definitive patholog-
ical involvement in disease is additionally derived from causal
familial mutations in the gene encoding TDP-43, TARDBP, in
ALS, which are principally though not exclusively found in the
glycine rich C-terminus [7].
It is unclear if one or several of these pathological TDP-43
alterations is a dominant driving mechanism in disease, and there
is evidence to support the toxicity of each in FTLD-TDP.
Pathological C-terminal fragments of the protein are more
aggregate-prone, undergoing phosphorylation, ubiquitination
and ultimately demonstrating cytotoxicity in cells [8,9,10].
Expression of TDP-43 containing disease linked mutations found
in ALS appears to increase the production of C-terminal
fragments, aggregation and toxicity [9,11,12]. Loss of TDP-
43 also appears to be deleterious to cell health; knockdown in vitro
confers toxicity and knockout results in lethality in vivo, both in utero
in constitutive Tardbp2/2 mice and in conditional knockout
animals in which deletion is postponed until adulthood
[13,14,15,16]. Loss of TDP-43 specifically in motor neurons
results in cell death and an ALS-like phenotype in mice [17] and
reduced TDP-43 expression in zebrafish and drosophila results in
motor deficits [18,19].
To determine if one mechanism is more dominant than others
in vivo, a host of constitutive and inducible transgenic rodents
expressing human or mouse (wild type and mutant) TDP-43 under
the control of various promoters have been created, which
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recapitulate some of the hallmark pathology of FTLD-TDP/ALS
including inclusions of ubiquitinated, phosphorylated TDP-43 and
TDP-43 immunoreactive lower weight molecular species
[20,21,22,23,24]. Here we describe the pathological and bio-
chemical characterization of two novel lines of mice conditionally
expressing human mutant M337V TDP-43, providing further
insight into the nature of neurodegenerative phenotypes in TDP-
43 expressing animal models.
Methods
Ethics Statement for Animal Care
All procedures were conducted according to the National
Institutes of Health guide for animal care and approved by the
Institutional and Animal Care and Use Committee at University
of Florida or Mayo Clinic.
Generation of Transgenic iTDP-43 Animals
iTDP-43 mice were generated similarly to a previously
described protocol [25]. Full length, untagged, M337V human
TDP-43 cDNA was created using the Quickchange II site directed
mutagenesis kit (Stratagene) using a TDP-43-myc plasmid as a
template [26], and was inserted into the inducible expression
vector pUHD 10–3 containing five tetracycline operator sequenc-
es. The construct was confirmed by restriction enzyme digest and
direct sequencing. The transgenic fragment was obtained by BsrBI
digestion, gel purified followed by b–agarase digestion (NEB),
filtration and concentration. The modified TDP-43 transgene was
injected into the pronuclei of donor FVB/NCr embryos (Charles
River). 14 founders were positive for the TDP-43 responder
transgene. These were then bred with 129S6 mice (Taconic) with
the tetracycline transactivator (tTA) transgene downstream of
calcium calmodulin kinase II alpha (CaMKIIa) promoter elements
[27] to produce the iTDP-43 transgenic mice with forebrain
hTDP-43 expression. 8 founders transmitted and expressed the
TDP-43 transgene and we subsequently chose the two founder
lines with the highest transgenic TDP-43 expression at 2 months of
age. All experimental mice used in this study were F1 hybrids
produced from a breeding of TDP-43 monogenic mice on a
congenic FVB/Ncr and tTA monogenic mice on a 129S6
background.
Antibodies
Antibodies used in this work are described in table s1. Epitopes
recognized by TDP-43 antibodies are detailed in figure s1.
Immunohistochemistry
After euthanasia via cervical dislocation, brains were harvested
and divided along the midline. The right hemisphere was flash-
frozen on dry ice, while the left hemisphere was drop fixed in 10%
neutral buffered formalin for histological analyses. Brains were
embedded in paraffin and cut into 5 mm sagittal sections. For
hTDP-43, caspase 3 and ubiquitin antibodies, tissues were
immunostained using the DAKO Autostainer (DAKO Auto
Machine Corporation, Carpinteria, CA) with DAKO Envision
HRP System. For p403/404 detection, sections were deparaf-
finzed and hydrated through a graded alcohol series prior to
antigen retrieval in citrate buffer (10 mM sodium citrate, 0.05%
Tween, pH 6.0) for 30 minutes in a steamer with water at a rolling
boil. Blocking was performed using DAKO Protein Block for 1 h
followed by incubation overnight with primary antibody at 4uC.
Peroxidase conjugated secondary antibody was visualized with
diaminobenzidine (Vector Labs, Burlingame, CA). Hematoxylin
and eosin (H&E) staining was performed by standard procedures.
Immunofluorescence
Sections were prepared as above, except visualization of
primary antibody was performed using Alexa Fluor 488 secondary
antibody (Invitrogen). Slides were dipped in Sudan Black to reduce
background autofluorescence and vectashield with DAPI (Vector
Laboratories) was used to stain nuclei. Images were captured using
an Olympus BX60 microscope (Olympus).
Protein Isolation, Fractionation and Western Blotting
To isolate SDS-soluble fractions, brain or dissected cortex was
homogenized in lysis buffer (50 mM Tris, 300 mM NaCl, 1%
Triton X-100, 1 mM EDTA with protease inhibitors and
phosphatase inhibitors (Sigma)) at 6 ml/g tissue, and aliquots of
homogenate stored at 280uC. Lysate was prepared via brief
sonication, addition of SDS to 1% and centrifugation at 40K6g
for 20 minutes at 4uC. For experiments using HEK293T cells, cells
were washed once with and then harvested in ice cold PBS. Cells
were then pelleted by brief centrifugation at 5006g and lysed in
lysis buffer as described above. 30–50 mg protein was loaded onto
10% or 15% Tris–glycine polyacrylamide gel (Novex). Following
electrophoresis and transfer, nitrocellulose membranes were
blocked with 5% milk in TBS-T (Tris-buffered saline with 0.1%
Triton X-100), incubated with appropriate primary and HRP-
conjugated secondary antibodies and visualized using ECL
reagent (Perkin-Elmer). Images were captured on the ProteinSim-
ple FluorChem E (ProteinSimple, Santa Clara, California). In all
cases where blotting was to be quantified, lysate prepared fresh
from homogenate was used, and following probing with antibody
of interest the blot was stripped (70 mM SDS in Tris HCl (pH 6.8)
with 0.7% BME for 30 minutes at 55uC) and re-probed with
loading antibody. Densitometry was performed using AlphaView
(ProteinSimple), and following normalization to loading controls,
fold changes calculated and unpaired t-test used to assess
significance.
To analyze solubility of TDP-43 fragments, cortex from P5
animals was homogenized in 5 ml/g of high salt buffer (10 mM
Tris pH 7.5, 5 mM EDTA, 10% sucrose, 1% triton, 0.5 M
NaCl, with protease and phosphatase inhibitors), incubated at
4uC for 15 minutes and clarified by centrifugation at 110K6g.
The supernatant containing the high salt fraction was snap
frozen on dry ice and the pellet washed and re-homogenized in
5 ml/g myelin floatation buffer (high salt buffer with 30%
sucrose). This homogenization, centrifugation and fraction
collection sequence was repeated with sarkosyl buffer (high salt
buffer substituting 1% triton for 1% N-lauroyl-sarcosine,
incubation 1 hour at room temperature), and finally in 1 ml/g
urea buffer (30 mM Tris pH 8.5, 4% CHAPS, 7 M urea, 2 M
thiourea, brief sonication). 50 ug of high salt extract and
equivalent volumes of all other fractions underwent Western
blotting as described above.
Quantitative Real Time PCR
Total RNA was isolated from dissected hippocampus or
cortex using TRIzol reagent (Life Technologies) and Pure Link
RNA Mini Kit (Life Technologies). During this step, DNA was
removed using on-column DNase digestion (Life Technologies)
and the resulting RNA purity and integrity was assessed on
spectrophotometer (Nanodrop, Wilmington, USA) and agarose
gel electrophoresis. 2 mg of RNA was used to synthesize cDNA
using the High Capacity cDNA Reverse Transcription Kit
(Applied Biosystems). All samples were run in triplicate on the
ABI 7900 HT Real-Time PCR Detection System using SYBR
green PCR master mix (Applied Biosystems). Primer efficiencies
(E) were calculated using E= 10(21/slope), where slope was
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determined by plotting the Cq (quantification cycle) values
against the log10 input of a cDNA dilution series. A 1/50
dilution of each experimental cDNA sample was run. From this,
the relative quantities (RQ) were calculated for each primer pair
in each sample and normalization of Tardbp performed using
the geometric mean of the two reference genes Gapdh and b-
actin, giving the Normalized Relative Quantity (NRQ) [28].
Primer sequences for qPCR were Tardbp1 F
(59AAAGGTGTTTGTTGGACGTTGTACAG 39), Tardbp1 R
(59 AAAGCTCTGAATGGTTTGGGAATG 39), Tardbp2 F (59
GATTGGTTTGTTCAGTGTGGAGTATATTCA 39), Tardbp2
R (59 ACAGCAGTTCACTTTCACCCACTCA 39), Tardbp3 F
(59 GGTGGTTAGTAGGTTGGTTATTAGGTTAGGTA 39),
Tardbp3 R (59 AAATACTGCTGAATATACTCCACACT-
GAACA 39), Gapdh F (59 CATGGCCTTCCGTGTTCCTA
39), Gapdh R (59 CCTGCTTCACCACCTTCTTGAT 39), b-
actin F (59 GATGACCCAGATCATGTTTGAGACCTT 39)
and b-actin R (59 CCATCACAATGCCTGTGGTACGA 39).
Single PCR products were verified by melt curve analysis.
Statistical significance was assessed using unpaired t-test.
TDP-43 Plasmid Generation
Full-length human TDP-43 complementary cDNA in plasmid
pEGFP-C1 [10] was used as PCR template to generate N-
terminally myc tagged TDP-43208–414 and TDP-431–280. The
primers used were TDP-43208–414 F (59-TACGGATCCCAC-
CATGGAACAAAAACTCATCTCAGAAGAGGATCTGCGG-
GAGTTCTTCTCTCAGTACGG-39); TDP-43208–414 R (59-
GAATCGCGGCCGCCTACATTCCCCAGCCAGAAGACT-
39); TDP-431–280 F (59-TACGGATCCCACCATGGAA-
CAAAAACTCATCTCAGAAGAGGATCTGATGTCTGAA-
TATATTCGGGTAACCGAA-39); TDP-431–280 R (59-
GAATCGCGGCCGCTCATGGATTACCACCAAATCTTC-
CAC-39). Products were cloned into pcDNA3.1 (Life Technolo-
gies) using BamH1 and Not1 sites and plasmids were verified by
sequence analysis.
Figure 1. Expression of human TDP-43 in iTDP-4314A and iTDP-438A mice in the postnatal period. Immunohistochemical detection of
hTDP-43 expression in cortex (CTX), hippocampus (HIP) and striatum (STR) in iTDP-4314A (A) and iTDP-438A (B). Western analysis of organs
demonstrated specificity of hTDP-43 expression to the brain in both iTDP-4314A (C) and iTDP-438A (D) (SC= spinal cord, He =heart, Lu = lung, Li = liver,
Ki = kidney, St = stomach, SM= skeletal muscle, Sp = spleen, Br = brain). (E) Brain weight measurement of non-transgenic (NT) and iTDP-4314A mice at
postnatal stages until 2 months of age (P60) (*p,0.05, **p,0.01, *** p,0.001, unpaired two tailed T-test). (F) Expression of hTDP-43 at indicated
postnatal time points for iTDP-4314A. (G) Expression of hTDP-43 at indicated postnatal time points for iTDP-4314A (14) compared to iTDP-438A (8).
doi:10.1371/journal.pone.0086513.g001
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Cell Culture and Transfection
Human Embryonic Kidney 293T cells were maintained in
Dulbecco’s Modified Eagle’s Medium (Lonza) supplemented with
10% Fetal Calf Serum (Sigma) and penicillin-streptomycin (Life
Technologies). Transfection in 6 well plates was performed for 48
hours using 2.0 ug of plasmid and Lipofectamine 2000 (Life
Technologies) following the manufacturer’s guidelines.
Results
Early, Rapid Postnatal Cell Loss Induced by hTDP-43M337V
Prevents Brain Development without Causing TDP-43
Aggregation
Fourteen monogenic, transgenic M337V hTDP-43 founder
lines were bred to animals expressing the tetracycline transacti-
vator (tTA) to produce bigenic iTDP-43 mice expressing human
mutant TDP-43. We initially screened iTDP-43 mice at two
months of age for expression of human TDP-43 and selected the
two highest expressing lines (14A and 8A) for further analysis.
Transgene expression in bigenic animals from both lines was
limited exclusively to the brain, predominantly in the cortex,
hippocampus and striatum (figure 1A–D), consistent with what has
been previously reported with this conditional system [24,27].
Phenotypically these animals did not display any premature death
or overt signs of neurological dysfunction as we and others have
reported in TDP-43 transgenic animals [22,24,29]. However,
while iTDP-438A animals developed normal brain structure, there
was obvious reduction in the cortical volume of iTDP-4314A brains
compared to non-transgenic (NT) littermates (figure 1A).
To fully characterize the progression of cortical degeneration in
iTDP-4314A, we examined postnatal ages from P0 to P60 to
determine the time point of initial phenotypic onset. During this
period, brain weights of NT mice experienced a rapid phase of
growth between P0 and P12, followed by more modest increases
into adulthood (figure 1E). iTDP-4314A mice however demonstrate
striking abnormalities in brain weight during postnatal develop-
ment. There was no difference in gross brain weight of iTDP-
4314A mice compared to NT mice at P0; however, iTDP-4314A
brain weight was reduced by 33% (NT=212 mg611, iTDP-
43= 143 mg611, p=0.002) by P5 and iTDP-4314A brain weight
never reached that of non-transgenic litter mates (figure 1E). This
phenotype was not observed in either monogenic tTA or
monogenic hTDP-4314A mice, and thus is a result of hTDP-43
expression in bigenic animals (figure s2A). Analysis using a human
specific TDP-43 antibody revealed large changes in observed
transgene expression over this time period. Peak transgene
expression at P5 coincided with age of phenotypic onset before
gradual reduction to the levels observed at P60 (figure 1F).
Although iTDP-4314A and iTDP-438A mice expressed similar
levels of human M337V TDP-43 in the initial screen at P60,
transgene expression in iTDP-438A mice at earlier time points was
far lower than in iTDP-4314A mice, likely explaining the
phenotypic difference between the two lines (figure 1G).
To examine the potential underlying mechanisms of neurode-
generation in iTDP-4314A, we screened for neuropathology
consistent with FTLD-TDP at P5, the earliest neurodegenerative
time point studied. Immunohistochemical detection of hTDP-
43M337V expression using human-specific antibody revealed
abundant expression in cortex, hippocampus and striatum
(figure 2A). To confirm active cell death, we used antibodies to
activated caspase 3. Western blotting of brain lysate revealed low
level activated caspase-3 in NT mice, which is compatible with
programmed apoptosis during developmental stages [30]; howev-
er, this was markedly increased in iTDP-4314A animals (figure 2B).
This was confirmed by immunohistochemical detection of
extensive activated caspase 3 immunoreactivity in the cortex of
iTDP-4314A mice (figure 2C), suggesting extensive cell death at P5
as a result of the expression of M337V TDP-43. We detected no
increase in activated caspase-3 by western blot in monogenic tTA
mice compared to NT mice, ruling out tTA expression as the
cause of this phenotype (figure s2B).
The end-stage neuropathology of FTLD-TDP is characterized
by the presence of ubiquitinated, phosphorylated TDP-43
aggregates in the cytoplasm of affected neurons and glia. We
used antibodies to ubiquitin, human TDP-43 (hTDP-43), total
TDP-43 (tTDP-43 Ab1) and TDP-43 phosphorylated at residues
403/404 (p403/404) and 409/410 (p409/410) to investigate the
contribution of aggregation to the cell death observed in P5 iTDP-
4314A mice. We qualitatively observed widespread, increased
ubiquitin immunoreactivity in the upper layers of the developing
cortex (figure 2C). Despite being exclusively cytoplasmic, the
staining was diffuse in nature and we found no evidence of
ubiquitin positive aggregates characteristic of FTLD-TDP. Fur-
thermore, we found no evidence of TDP-43 aggregation using
hTDP-43, tTDP-43, p403/404 or p409/410 antibodies
(figure 2D). We did frequently detect cytoplasmic human TDP-
43 staining in iTDP-4314A mice within the cortex; however, no
aggregates were observed. Both tTDP-43 and p409/410 antibod-
ies showed abundant cytoplasmic reactivity in NT mice, suggesting
that this is a spatiotemporally normal distribution (arrowheads in
figure 2D). Therefore, cell death at the earliest stage investigated
occurred in the complete absence of cytoplasmic or nuclear TDP-
43 aggregates of any kind.
Misprocessing of Human TDP-43 is a Feature of Early
Neurodegeneration
The cleavage of TDP-43 into a variety of detergent-insoluble,
urea soluble fragments ranging from 17–35 kDa is a hallmark of
FTLD-TDP and these fragments are a potential source of
neuronal toxicity [1,5,6]. Transgenic mice expressing wild type
or familial ALS-linked mutant TDP-43 are characterized by the
presence of 35 kDa and 25 kDa TDP-43 immunoreactive species
[7,21,29,31,32,33,34,35]. However, the nature of these species is
largely unknown. We used a panel of antibodies raised to the N-
terminus (residues 3–12), C-terminus (405–414), and central RRM
domains of TDP-43 (tTDP-43Ab1 and tTDP-43 Ab2) to
determine the extent and nature ofTDP-43 fragmentation in P5
iTDP-4314A mice. To validate the antibodies used, we overex-
pressed either a C-terminal pathological fragment identified in
human cases of FTLD-TDP (TDP-43208–414) [36] or the first 280
amino acids of human TDP-43 (TDP-431–280), both with an N-
terminal myc tag, in HEK293T cells. Subsequent western analysis
of lysate verified that the C-terminal antibody detected TDP-
43208–414, but not TDP-431–280. Conversely, tTDP-43 Ab2, which
is raised to residues 181–198, detected TDP-431–280 but not TDP-
43208–414. Human specific antibody and myc antibody detected
both. TDP-43 3–12 detected TDP-431–280 but not the C-terminal
fragment (figure s3). These findings are consistent with the
antigenic epitopes of these antibodies and epitope mapping studies
previously published [37,38].
In SDS soluble fractions of P5 brain lysate from iTDP-4314A
mice, we detected species of approximately 35 kDa (TDP-35) and
25 kDa (TDP-25) using total TDP-43 Ab1 and total TDP-43 Ab2
(figure 3A). Both of these antibodies recognize epitopes in the
second RNA recognition motif of mTdp-43 and hTDP-43, which
is located in the center of TDP-43. However, we failed to detect
either of these low molecular weight species using antibodies raised
Divergent Phenotypes in TDP-43 Transgenic Mice
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Figure 2. Early degenerative phenotype in iTDP-4314A mice at P5 in the absence of FTLD-like TDP-43 aggregation. (A) Monoclonal
antibody to human TDP-43 showed expression at P5 remained restricted to previously characterized regions of hippocampus, cortex and striatum. (B)
Western blotting of brain lysate of P5 non-transgenic (NT) and iTDP-4314A demonstrated increased levels of activated caspase 3 in iTDP-4314A mice.
(C) Abundant caspase 3 immunoreactivity in the cortex of iTDP-4314A mice that was virtually absent in NT mice, suggestive of elevated cell death in
iTDP4314A compared to NT mice. iTDP-4314A mice were also characterized by increased ubiquitin staining in the upper layers of the cortex compared
to NT mice, which upon higher magnification appeared to be completely diffuse and cytoplasmic. (D) Immunohistochemistry for hTDP-43 and p403/
404 and immunofluorescence using antibodies to total TDP-43 and p409/410 TDP-43. Significant amounts of cytoplasmic hTDP-43 were observed in
iTDP-43 mice (arrowheads). Note that this cytoplasmic staining was also observed in NT mice (arrowheads) with antibodies to total TDP-43 (tTDP-43
Ab1) and TDP-43 phosphorylated at 409/410 (p409/410). Scale bars in D= 50 mm.
doi:10.1371/journal.pone.0086513.g002
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to the C-terminus (residues 405–414) or N-terminus (residues 3–
12) of TDP-43 (figure 3A).
To assess the solubility of TDP-43, TDP-35 and TDP-25, we
used a series of increasingly stringent buffers to sequentially extract
protein from cortical tissue of p5 iTDP-4314A mice. Western
blotting of the resulting fractions and analysis using human specific
TDP-43 antibody demonstrated that although a proportion of
TDP-35 was detergent insoluble but urea soluble, the majority of
TDP-35 and TDP-25 are soluble in high salt buffer (figure 3b).
Consequently, during early neurodegeneration in iTDP-4314A,
TDP-43 fragments are derived from a central portion of human
TDP-43 and are largely soluble.
Another cardinal feature of FTLD-TDP is loss of nuclear TDP-
43, which may contribute to disease via aberrant transcriptional
control and/or misprocessing of RNA substrates bound by TDP-
43 [2]. In a previously published transgenic line expressing human
wild type TDP-43, loss of murine Tdp-43 (mTdp-43) occurred
upon human TDP-43 transgene expression and correlated with
phenotypic progression, suggesting that loss of mTdp-43 may be
analogous to loss of nuclear TDP-43 in human disease [23] despite
human transgene expression in the nucleus. Using an antibody
specific to mTdp-43, we detected a 33% decrease in the expression
of mTdp-43 in iTDP-4314A brain extract compared to NT
animals (0.6760.03, p=0.007 unpaired two tailed t-test,
figure 3C and D).
Low Level Misprocessing of TDP-43 is Well Tolerated
in vivo
Given the lack of an overt neurodegenerative phenotype in the
second iTDP-438A line, we aged iTDP-438A cohorts to 10 and 25
months. In both cohorts, brain weights of both tTA monogenic
and iTDP-438A mice were reduced 5–7% compared to NT (10 M:
NT=49666 mg N=5, iTDP-438A= 46264 mg N=7,
tTA=464.969 mg N=7, p,0.05 one way ANOVA Bonferroni
post-hoc analysis; 25 M: NT=50568 mg N=7, iTDP-
438A = 47067 mg, tTA=47367 mg, p,0.05 one way ANOVA
Bonferroni post-hoc analysis, figure s4) and there was decreased
volume of the dentate gyri, a previously documented observation
that likely reflects a phenotype driven by this tTA line rather than
the expression of the TDP-43 transgene [32]. With this exception,
we observed no phenotype in these animals as assessed by gross
weight or brain morphology using hematoxylin and eosin staining
(figure s4). We verified that expression of tTA did not alter the
levels of endogenous mTdp-43 or the abundance of lower
molecular weight TDP species (figure s4). Therefore, although
tTA expression results in reduced brain weight in older mice, it
does not alter TDP-43 biochemistry.
Due to the lack of an overt phenotype, we hypothesized that any
TDP-43 biochemical alterations in the iTDP-438A line may be
small in magnitude. In order to increase detection of low level
alterations over background, we used lysate of dissected cortex as
opposed to brain lysate, thus enriching hTDP-43M337V expressing
regions and reducing noise from regions not expressing the
transgene. Expression levels of the hTDP-43M337V transgene were
exceptionally low in both the 10 and 25 month iTDP-438A
cohorts. Western blotting and densitometry analysis of cortical
extracts using tTDP-43 Ab2 demonstrated ,1.25 fold overex-
pression of TDP-43 compared to NT mice (10 M=1.2260.07,
25 M=1.3360.05, figure 4A, quantification in 4B). In both
cohorts, increased levels of TDP-35 but not TDP-25 was observed
relative to control mice (10 M TDP-35= 1.3260.09, p=0.049;
10 M TDP-25= 1.0860.05, p=0.396; 25 M TDP-
Figure 3. Biochemistry of iTDP-4314A brain lysates at P5. (A) Western blotting using two antibodies to total TDP-43 (tTDP-43 Ab1 and tTDP-43
Ab2) demonstrated increased levels of low molecular weight species at 35 kDa (arrow) and 25 kDa (arrowhead) in iTDP-4314A mice relative to NT
mice. These species were not observed using antibodies to the C-terminus (405–414) or N-terminus (3–12) of TDP-43. (B) Western blot analysis of high
salt (HS), myelin floatation buffer (MFB), sarkosyl (SARK) and urea fractions using antibody to human TDP-43. Note that human TDP-35 (arrow) is
present in the urea fraction but is absent from MFB and SARK fractions, N= non-transgenic, T = iTDP-4314A. (C) Antibody to murine Tdp-43
demonstrated reduction of mTdp-43 in brain compared to NT mice. (D) Quantification of blot in (C), **p,0.01, unpaired two tailed t-test.
doi:10.1371/journal.pone.0086513.g003
Divergent Phenotypes in TDP-43 Transgenic Mice
PLOS ONE | www.plosone.org 6 January 2014 | Volume 9 | Issue 1 | e86513
35= 1.3060.08, p=0.026; 25 M TDP-25= 1.1660.16 p=0.353,
figure 4A and B). We also measured levels of mTdp-43 protein in
cortical extracts of both cohorts and found it to be downregulated
in iTDP-438A compared to controls (10 M=0.7160.07, p=0.017;
25 M=0.6760.05, p=0.005; figure 4C, D and E). Given that
TDP-43 autoregulates the abundance of Tardbp mRNA in vivo and
in vitro [2,39], we used quantitative PCR to examine levels of
murine Tardbp transcript. Using three different primer pairs to
Tardbp, we found no evidence in the cortex of 25 month old
animals for the downregulation of murine Tardbp transcript in
iTDP-438A mice compared to control animals (figure 4F).
Additionally, we failed to detect downregulation in the cortex
and hippocampus of 2 month old iTDP-438A animals (figure 4F).
Seeking to validate our methodology, we analyzed hippocampal
RNA from a line of transgenic mice overexpressing human wild
type TDP-43, iTDP-4317D, that have previously been reported to
express reduced Tardbp mRNA [24]. We observed a statistically
significant reduction in Tardbp using all three primer pairs
(figure 4F). These data suggest that additional mechanisms may
exist in vivo that regulate Tdp-43 levels independent of Tardbp total
transcript levels.
To determine the neuropathogical consequences of low level
M337V TDP-43 expression in the older 25 M cohort, we again
examined markers of FTLD-TDP pathology. The cortex of 25 M
old iTDP-438A animals was characterized by rare cells bearing
intense ubiquitin reactivity, predominantly in the lower cortical
layers (figure 5A and B). This increased staining for ubiquitin was
both nuclear and cytoplasmic (inset, figure 5A), which contrasts
Figure 4. Loss of murine Tdp-43 and increased TDP-35 in 25 month (25 M) iTDP-438A. (A) Analysis of transgene expression in 10 M and
25 M cohorts using hTDP-43 and tTDP-43 Ab2 antibodies, b-actin for loading. (B) Densitometric quantitation of TDP-43, TDP-35 and TDP-25 from blot
in (A), represented as relative levels of TDP species following sample normalization to b-actin loading controls. (C) mTdp-43 expression in 10 M iTDP-
438A, b-actin loading control. (D) mTdp-43 expression in 25 M iTDP-438A, b-actin loading control. (E) Densitometric quantitation of reduction in mTdp-
43 protein levels from blots in (C) and (D), represented as relative levels of mTdp-43 following sample normalization to b-actin loading controls. (F)
Quantitative PCR analysis of Tardbp transcript in 2 month old transgenic (T) iTDP-4317D mice hippocampus (HIP) using Tardbp primers 1, 2 and 3
detected significant reduction in murine Tdp-43 mRNA levels compared to nontransgenic (N) mice and acted as a positive control for our
methodology (N= 3 per genotype). No reduction in Tardbp mRNA was detected in the cortex (COR) and hippocampus of 2 month (2 M) iTDP-438A
mice relative to nontransgenic mice using murine-specific Tardbp primer pair 1 (N= 3 per genotype). No downregulation of Tardbp was observed in
the cortex of 25 M iTDP-438A (N=3) relative to control (C) mice (N= 4), using Tardbp primers 1, 2 or 3. Values shown as Normalized Relative Quantity,
see Materials and Methods for further details. Control at 25 M consisted of 2 non-transgenic and 2 tTA mice. In graphs (B),(E) and (F): *p,0.05,
**p,0.01, unpaired t-test, error bars are SEM.
doi:10.1371/journal.pone.0086513.g004
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with the exclusively cytoplasmic distribution in P5 iTDP-4314A
mice. As in P5 iTDP-4314A mice, we found no evidence of TDP-
43 aggregation using hTDP-43, tTDP-43, p403/404 or p409/410
antibodies (figure 5C). Although we observed neurons in iTDP-
43 mice bearing hTDP-43 reactivity in the cytoplasm, numerous
cells were observed in both NT and iTDP-43 mice with
cytoplasmic tTDP-43, p409/410 and p403/404 (arrowheads in
figure 5C). In conjunction with our biochemical analysis, this
evidence suggests that an approximately 30% reduction in mTdp-
43 in the presence of low level expression of hTDP-43 and
simultaneous low level increases in TDP-35 result in relatively
minor neuropathological abnormalities and are well tolerated even
over long time spans.
Discussion
TDP-43 plays a major role in the pathogenesis of FTLD-TDP.
Mutations in TARDBP cause some cases of TDP-43-proteinopathy
in amyotrophic lateral sclerosis. Numerous transgenic rodents
overexpressing wild type or mutant TDP-43 have been reported
that have developed profound neurodegenerative phenotypes,
early lethality and gait abnormalities. Some features of FTLD-
TDP and/or ALS have been recapitulated in these transgenic lines
including aggregated, hyperphosphorylated TDP-43, and mis-
processing of TDP-43 into lower molecular weight species.
In this paper, we generated two lines of mice expressing human
TDP-43 containing the familial M337V mutation driven by the
CaMKIIa promoter to determine the effects of mutant TDP-43
expression in the forebrain. Of note, neither iTDP-43 line
exhibited overt phenotype comparable to previous reports (early
lethality, weight loss, limb weakness or gait disturbances). As
transgenic lines driven by the CaMKIIa promoter or bearing the
M337V mutation have already been reported that do exhibit these
phenotypes [21,24,33], the absence here of early lethality or gait
disturbance cannot be entirely explained by these variables alone,
suggesting that a combination of these and other factors such as
timing of transgene expression and background strain govern
ALS-like phenotypes.
The human neuropathology of FTLD-TDP - consisting of loss
of nuclear TDP-43, TDP-43 aggregation, phosphorylation and
fragmentation to C-terminal lower molecular weight species - has
driven hypotheses as to TDP-43 toxicity both in human disease
and in mice expressing transgenic TDP-43. Herein, we found that
early neurodegeneration in the iTDP-4314A mouse line occurred
in the complete absence of aggregation. This observation is
consistent with previous research demonstrating that aggregation
does not appear to be a major driver of cell death in TDP-43
transgenic animals [22,23]. However, we cannot rule out that
aggregates may be neurotoxic, particularly in lines in which they
feature more prominently [21,24]. In contrast, downregulation of
endogenous mTdp-43 is a feature of early degeneration in iTDP-
Figure 5. Neuropathology of 25 month old iTDP-438A mice. Immunohistochemical detection of ubiquitin revealed rare cells bearing increased
ubiquitin staining in the cortex of iTDP-438A mice (arrows, A) that was absent in NT animals (B, scale bar = 200 mm). Staining was detected in both
nucleus and cytoplasm of affected cells (inset in A, scale bar = 10 mm). (C) In iTDP-438A animals hTDP-43 was predominantly nuclear, some cells
displaying cytoplasmic localization without aggregation. Cytoplasmic localization was observed in NT and iTDP-438A mice using antibodies to total
TDP-43 (tTDP-43 Ab1) and phosphorylated forms of TDP-43 (p403/404, p409/410).
doi:10.1371/journal.pone.0086513.g005
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4314A, and this has been implicated elsewhere as a potential driver
of neurodegeneration where it correlates with phenotypic
progression [23]. However, data from our second line iTDP-
438A – in which we observed downregulation of mTdp-43 of 30%
until 25 months of age, the oldest age examined – indicates that if
loss of murine Tdp-43 is capable of driving aggressive neurode-
generative phenotypes, a critical threshold must be reached.
Interestingly, we failed to detect downregulation of murine Tardbp
transcript in either young or aged iTDP-438A cortex despite the
reduction in mTdp-43 protein. This contrasts with findings from
our lab and elsewhere demonstrating in vivo, hTDP-43 autoregu-
lated reduction in Tardbp as the underlying mechanism of reduced
Tdp-43 [2,20,33]. This finding may be indicative of other post-
transcriptional autoregulatory activity (for example, TDP-43
mediated translational repression [40]) or that the subtle
phenotype observed in aged iTDP-438A mice is sufficient to cause
a measurable reduction in Tdp-43.
A potential additional source of neurotoxicity in iTDP-4314A
may be fragmentation of TDP-43 to the low molecular weight
species TDP-35 and TDP-25. At the earliest phenotypic time
point studied here, we observed accumulation of these species at
least partially derived from the human TDP-43 transgene and
found evidence of detergent insoluble, urea soluble TDP-35.
Although these species may be inherently neurotoxic and
contribute to cell death in iTDP-4314A, we also determined that
they are derived from a central portion of TDP-43 and are thus
may not be biochemically identical to the C-terminally derived
fragments of human disease. Consequently, we cannot be certain
that any neurotoxicity these species invoke is relevant to human
pathology. More study is required to determine if these fragments
are identical to those almost universally present in other TDP-43
transgenic animals. Elsewhere, these fragments have been
described as C-terminal in nature, based on the use of antibodies
raised to the C-terminal 154 residues of TDP-43 [20]. To our
knowledge the epitope of this polyclonal antibody has not been
mapped. However, as a large proportion of the immunogen
corresponds to the center of TDP-43, it is possible this ‘C-terminal’
antibody detects centrally derived fragments also.
Consequently, our data here add to prior studies suggesting that
neurodegenerative phenotypes in existing TDP-43 transgenic
animals might be influenced by a number of factors depending
on the transgenic line, and that it may prove difficult to separate
toxicity of potentially disease relevant phenomena from one
another or from global RNA dysregulation that occurs upon
mutant TDP-43 overexpression [41]. Additionally, the phenotype
in iTDP-4314A is aggressive and occurs prior to full development of
the brain, an effect that we have documented in a previous line
constitutively expressing wild type TDP-43 and that may be the
case in several other high expressing transgenic lines with early
phenotypes [20,22,24,29,33]. This clearly makes for a poor model
of an age-related neurodegenerative condition. While existing
TDP-43 transgenic mice will undoubtedly provide insight into
TDP-43 function and in some instances can be used as
investigative tools, the field still lacks in vivo models that faithfully
recapitulate age dependent accumulation of disease relevant TDP-
43 pathology.
Supporting Information
Figure S1 TDP-43 antibodies used in this study. N-terminal, C-
terminal, mTDP-43 and tTDP-43 Ab2 are raised to the indicated
epitopes. hTDP-43 and tTDP-43 Ab1 antibodies have been
mapped to the indicated epitopes in previous studies [37,38].
Murine Tdp-43 specific antibody was raised as previously
described [42].
(TIF)
Figure S2 tTA expression is not responsible for iTDP-4314A
phenotypes. (A) Brain weights of NT, monogenic hTDP-4314A and
monogenic tTA mice at P5 and 2 months of age were identical. (B)
Western analysis of P5 brain lysate demonstrated no increase in
activated caspase 3 in tTA only mice compared to NT mice.
However, elevated activated caspase 3 was observed in iTDP-
4314A.
(TIF)
Figure S3 Validation of TDP-43 antibody specificity. Western
analysis of lysate from HEK-293T cells transfected with empty
vector, myc-hTDP-431–280 or myc-hTDP-43208–414. Blots were
probed with the indicated antibodies.
(TIF)
Figure S4 Expression of tTA trangene does not affect TDP-43
metabolism. (A) Brain weights of iTDP-438A mice covering the
postnatal period and aged cohorts. No significant difference in
weight was observed in the time period to 2 months; tTA and
iTDP-43 mice in 10 month and 25 month cohorts showed a small,
significant decrease relative to NT mice (N(P0) = 4 per genotype;
N(P12) = 3 per genotype; N(P21) = 4 per genotype; N(2 M) = 5 per
genotype; N(10 M)= 5 NT, 8 iTDP-43, 7 tTA; N(25 M)= 7 NT,
7 iTDP-43, 5 tTA. Error bars are SD, *p,0.05, one way
ANOVA, Bonferroni post hoc). (B) Hematoxylin and eosin staining
of 25 M cohorts from line iTDP-438A show no gross morpholog-
ical differences between tTA and iTDP-438A cortex. There was a
trend toward smaller dentate gyri in tTA mice compared to NT
mice. (C) Long exposure of western blot of 11 M NT and tTA
cortical lysates using antibody to total TDP-43 (tTDP-43 Ab2),
mouse specific TDP-43 antibody was used to probe same lysates,
b-actin for loading. (D) Densitometric quantitation of blots in (C)
confirmed no change in TDP-43, TDP-35 or TDP-25 in tTA
mice versus NT mice; values are represented as fold change
relative to NT mice following sample normalization to b-actin
loading controls.
(TIF)
Table S1 Primary antibodies used in this study.
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